| Similar Articles |
|---|
 |
Pharmaceutical Executive
July 1, 2009 |
The Pharmerging Future A guide to grabbing growth in seven "pharmerging" markets.   |
Pharmaceutical Executive
October 1, 2011 |
Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy. |
The Motley Fool
May 11, 2010
Brian Orelli |
Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40. |
Pharmaceutical Executive
October 1, 2006
Ray Hill |
China: Big Rewards. Bigger Risks? The world's fastest growing pharmaceutical market may one day be the largest. Breaking in could be industry's greatest challenge. |
Pharmaceutical Executive
August 1, 2011
Ben Comer |
Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever. |
Pharmaceutical Executive
June 1, 2011 |
Are You Ready for the New China? The ability to act as a good corporate citizen and assert a useful role in national industrial policy on health is going to be essential to success in the new China. |
Pharmaceutical Executive
November 1, 2008 |
No Ordinary Joe It's been a year since consumer marketing master Joe Jimenez took over the top spot at Novartis Pharma. How's he faring? |
Investment Advisor
January 2007
Melanie Waddell |
A Healthy New Year Growth of Health Savings Accounts (HSAs) and pricing pressure on brand name pharmaceutical manufacturers are among the top seven healthcare industry issues identified in a new report. |
Pharmaceutical Executive
February 1, 2011
Jon Zifferblat |
China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country |
Pharmaceutical Executive
March 1, 2013 |
China and the Emerging Markets Challenge: Why Big Pharma Must Embrace a New Strategy With health reform already tagged as a key domestic priority, their policies will pose new opportunities and challenges for Big Pharma companies active in China. |
Information Today
October 29, 2015 |
Thomson Reuters Streamlines Healthcare Industry Analysis Thomson Reuters rolled out the Healthcare Intelligence application for Thomson Reuters Eikon to improve workflow for financial professionals. |
The Motley Fool
April 12, 2011
Brian Orelli |
Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets. |
The Motley Fool
September 24, 2008
Brian Lawler |
Sanofi Gets the Golden Ring Sanofi-Aventis raises its bid and acquires Czech generic drugmaker Zentiva. |
The Motley Fool
May 21, 2010
Brian Orelli |
Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea. |
The Motley Fool
March 26, 2007
Rich Duprey |
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note. |
Pharmaceutical Executive
July 30, 2007
Peter Pitts |
Opinion: Fewer Cents, More Sense Our healthcare system may be broken, but playing the blame game is not going to fix it. Remember that disease - not Big Pharma - is the enemy. |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive
February 1, 2009
Patrick Clinton |
Working Together No one who cares about global health can be happy with a system that only "eventually" delivers drugs and vaccines for the planet's neediest people. |
Chemistry World
July 25, 2012 |
Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population. |
Investment Advisor
May 2010
Ron Pechtimaldjian |
Tax Implications Taxes are, for a change, probably the easiest area to consider when assessing the implications of healthcare reform for advisors and their clients. |
Pharmaceutical Executive
June 1, 2013
Tom Reynolds |
Finding Strategic Levers in the Supply Chain Customer-focused supply-chain capabilities are becoming a more important part of a company's competitive advantage. |
Pharmaceutical Executive
September 1, 2012
Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
The Motley Fool
July 31, 2009
Brian Orelli |
Can Emerging Markets Save Pharma? Probably not until after they emerge. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Pharmaceutical Executive
May 6, 2014
Adjei et al. |
Africa: The Lost Continent No More Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth. |
The Motley Fool
April 5, 2011
Frank Vinluan |
GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep. |
Pharmaceutical Executive
August 1, 2011
William Looney |
Paying for Health -- The Right Way What Big Pharma fails to see is how engagement in health policy is the biggest of reputation builders |
Financial Planning
February 1, 2005
Neil A. O'Hara |
The Harvest to Come Pharmaceutical stocks may be down, but they're hardly out. For planners and clients who can tolerate the risk of concentration, a selective allocation to the healthcare industry today may represent the ability to buy growth at a value price. |
The Motley Fool
July 11, 2007
Brian Lawler |
Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note. |
Pharmaceutical Executive
October 1, 2005
Philip A. George |
Backpage: Under Surveillance Doctors and consumers don't doubt that pharma benefits society. But in the eyes of the public, industry efforts to monitor postmarket safety come up short. |
Pharmaceutical Executive
December 1, 2012
Jill Wechsler |
Obamacare, Innovation and Pricing Tax and budget decisions will shape the healthcare market and drug research and regulation. |
Chemistry World
June 5, 2009
Anna Lewcock |
Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts. |
CRM
July 1, 2007
Marshall Lager |
Market Focus: Healthcare: The Great Divide The healthcare industry continues to have issues defining itself and its approach to CRM - but that's because it's more than one industry: the business of medicine and the care of patients. |
Pharmaceutical Executive
September 1, 2008
Patrick Clinton |
Attack of the Junk The United States makes the best medicines in the world. In days to come, that could be a problem. |
Pharmaceutical Executive
August 1, 2013
Joseph Saba |
New Rules for a New Africa Declining revenue growth in the United States and Europe have sent pharmaceutical companies in search of opportunities in the BRICs and other emerging economies. Now, companies are finally turning their attention to Africa. |
Pharmaceutical Executive
August 1, 2005
Lena Chow |
Docs of Shanghai They're short on status, pay, and respect, but China's young doctors hold keys to the world's fastest growing pharmaceutical market. |
IndustryWeek
August 1, 2007
Jill Jusko |
Design For Emerging Markets Many manufacturers want to break into emerging markets in a major way to develop and sell their goods, but simply making minor adjustments to their existing products isn't the best route to long-term success. |
Chemistry World
March 25, 2010
Rebecca Trager |
Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'. |
Chemistry World
January 11, 2013
Andrew Turley |
Pharma industry 'strategic crisis' The pharma industry is grappling with a 'strategic crisis' according to three quarters of companies surveyed in a report from consultancy firm Roland Berger. |
Pharmaceutical Executive
October 1, 2006 |
Sales and Marketing: Where the Buck Stops Pharma's ultimate customer is the employer - the guy who pays the health plan's bill. Here's what he wants to know about drugs. |
Registered Rep.
September 26, 2011
Stan Luxenberg |
Despite Ill Winds, Health Stocks Look Healthy Health stock valuations look compelling, and many companies should report solid earnings growth. |
Pharmaceutical Executive
June 1, 2009 |
Emerging Leaders 2009: The Faces of Innovation Meet 2009's emerging leaders - 27 industry pioneers under age 45 who are bringing new ideas to life. |
Job Journal
August 26, 2007
Michael Kinsman |
Career Pros: No Cure for Healthcare Costs? Has healthcare coverage become too costly for employers to provide? |
Financial Planning
April 1, 2006
Donald Jay Korn |
Rx for Investing Healthcare stocks may cure investors' ills over the long term, but the current prognosis is less clear. For clients in diversified funds, planners should decide whether additional healthcare exposure is justified, through individual stocks or specialized funds. |
The Motley Fool
October 28, 2009
Brian Orelli |
Saved by Emerging Markets. Sort Of. GlaxoSmithKline's top line looks good, but the bottom is what counts. |
Pharmaceutical Executive
October 1, 2011 |
The Legacy of High Expectations Andrew Witty, Chairman & CEO, GlaxoSmithKline, believes the pharmaceutical industry will continue to make a significant contribution to society if it continues to improve the way it goes about its work. |
CRM
July 1, 2009
Dave Rich |
New Routes to New Customers A customer-centric approach for emerging markets. |
The Motley Fool
March 15, 2004
W.D. Crotty |
60 Minutes on Drugs Will the weekly news magazine's prime-time slam rattle the drug stocks? |
Registered Rep.
October 29, 2010
Stan Luxenberg |
Emerging Market Stocks Still Have Room To Rise With economies soaring in Asia and Latin America, stocks have climbed throughout the emerging markets over the past decade. |
InternetNews
August 25, 2010 |
Security, EMRs Top Healthcare IT Priorities With new government regulations placing even more responsibility and scrutiny on the healthcare industry, IT administrators are struggling to deliver both efficiency and security. |
